Valuation: Adaptive Biotechnologies Corporation

Market Cap 4.54B 4.14B 3.83B 3.46B 6.5B 424B 6.8B 46.29B 18.36B 229B 17.04B 16.68B 726B P/E 2026 *
-71.2x
P/E 2027 * -510x
Enterprise Value 4.3B 3.92B 3.63B 3.28B 6.16B 402B 6.45B 43.87B 17.4B 217B 16.14B 15.81B 688B EV / Sales 2026 *
14x
EV / Sales 2027 * 11.4x
Free-Float
98.54%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week-4.85%
Current month+5.29%
1 month+17.12%
3 months+10.04%
6 months+116.44%
Current year+72.72%
1 week 27.29
Extreme 27.29
29.8
1 month 23.82
Extreme 23.82
32.21
Current year 12
Extreme 12
32.21
1 year 12
Extreme 12
32.21
3 years 2.28
Extreme 2.28
32.21
5 years 2.28
Extreme 2.28
32.21
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 07/09/2009
Director of Finance/CFO 42 07/04/2024
President 54 31/01/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 31/01/2013
Director/Board Member 70 30/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Exercice

Chairperson

35,643 0.0223%
29/10/26 Exercice

Chairperson

35,643 0.0223%
26/10/26 Exercice

Chairperson

35,643 0.0223%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-4.85%+85.15%+550.81% 4.54B
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.65%-2.94%+6.18%+89.17% 58.91B
-1.15%-0.87%+24.57%+84.83% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
0.00%+1.28%+78.44%+57.30% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +1.72%-0.84%+39.64%+216.34% 41B
Weighted average by Cap. +1.29%-1.02%+33.71%+158.06%

Financials

2026 *2027 *
Net sales 307M 280M 259M 234M 439M 28.67B 460M 3.13B 1.24B 15.49B 1.15B 1.13B 49.07B 374M 341M 316M 286M 536M 34.96B 561M 3.82B 1.51B 18.89B 1.4B 1.37B 59.84B
Net income -63.64M -57.98M -53.67M -48.55M -91.08M -5.94B -95.33M -649M -257M -3.21B -239M -234M -10.17B -9.66M -8.8M -8.14M -7.37M -13.82M -902M -14.46M -98.44M -39.05M -487M -36.22M -35.47M -1.54B
Net Debt -238M -217M -200M -181M -340M -22.19B -356M -2.42B -961M -11.99B -892M -873M -37.99B -266M -243M -225M -203M -381M -24.89B -399M -2.72B -1.08B -13.45B -1B -979M -42.6B
Projected Income Statement - Annual - Adaptive Biotechnologies Corporation
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
19/11/26 US$28.05 -1.44% 1,894,447
18/11/26 US$28.46 -0.11% 2,209,991
17/11/26 US$28.49 +2.22% 1,938,192
16/11/26 US$27.87 -4.03% 2,657,890
13/11/26 US$29.04 -1.49% 2,063,762
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Adaptive Biotechnologies Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
28.05USD
Average target price
33.86USD
Spread / Average Target
+20.70%
  1. Stock Market
  2. Stocks
  3. ADPT Stock